Cytosorbents Co. (NASDAQ:CTSO - Get Free Report) CFO Peter J. Mariani bought 11,363 shares of Cytosorbents stock in a transaction that occurred on Wednesday, December 11th. The stock was purchased at an average cost of $0.89 per share, with a total value of $10,113.07. Following the completion of the acquisition, the chief financial officer now directly owns 361,363 shares in the company, valued at $321,613.07. This represents a 3.25 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Cytosorbents Trading Up 13.4 %
Cytosorbents stock opened at $1.01 on Friday. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The firm's 50 day moving average price is $0.98 and its 200-day moving average price is $1.02. Cytosorbents Co. has a 1 year low of $0.70 and a 1 year high of $2.15. The stock has a market cap of $55.23 million, a P/E ratio of -2.81 and a beta of 0.57.
Institutional Trading of Cytosorbents
Hedge funds have recently bought and sold shares of the stock. CM Management LLC increased its holdings in shares of Cytosorbents by 3.0% in the second quarter. CM Management LLC now owns 850,000 shares of the medical research company's stock worth $598,000 after purchasing an additional 25,000 shares during the last quarter. Sargent Investment Group LLC raised its holdings in shares of Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company's stock worth $1,008,000 after acquiring an additional 67,181 shares in the last quarter. Atomi Financial Group Inc. bought a new position in shares of Cytosorbents during the 3rd quarter valued at approximately $51,000. Finally, Geode Capital Management LLC grew its holdings in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock valued at $701,000 after purchasing an additional 32,415 shares in the last quarter. Hedge funds and other institutional investors own 32.87% of the company's stock.
Analyst Ratings Changes
MUST SEE: The most important video in the world right now?
From InvestorPlace | Ad
If you have a significant amount of money in the stock market right now — or if you're sitting on the sidelines waiting to make a move — you DO NOT want to miss my latest research.
My goal is to get as many people as I can in front of what's coming.
If you wait until your hand is forced, it will already be too late.
And he's just issued an astonishing financial prediction.
A number of analysts have recently issued reports on the stock. HC Wainwright reissued a "neutral" rating and issued a $1.00 price objective on shares of Cytosorbents in a research note on Monday, November 11th. StockNews.com began coverage on Cytosorbents in a report on Thursday. They set a "hold" rating on the stock.
View Our Latest Report on CTSO
About Cytosorbents
(
Get Free Report)
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
